Pfizer Inc. topped first-quarter analyst estimates thanks to strong sales from the innovative drug business and raised its full-year forecast for adjusted earnings and sales. Bloomberg's Cynthia Koons recaps Pfizer's results and examines the possibility of a spinoff of the company’s innovative drug business. She speaks on "Bloomberg ‹GO›."
